Emerging roles for cysteine proteases in human biology

Annual Review of Physiology

Volumn 59, Issue , 1997, Pages 63-88

  Chapman, Harold A ^a   Riese, Richard J ^a   Shi, Guo Ping ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cathepsin; lung; macrophage; MHC class II; thiol protease

Indexed keywords

CATHEPSIN; COLLAGEN; CYSTEINE PROTEINASE; ELASTIN; INTERLEUKIN 1BETA CONVERTING ENZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PAPAIN; THIOL PROTEINASE;

ANTIGEN PRESENTATION; APOPTOSIS; ATHEROSCLEROSIS; BONE DEVELOPMENT; COLLAGEN DEGRADATION; ELASTOLYSIS; EMPHYSEMA; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; IMMUNE RESPONSE; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LYSOSOME; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW;

AMINO ACID SEQUENCE; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 0030970119     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.59.1.63     Document Type: Review

References (120)

1. Neurath H, Walsh KA. 1976. Role of proteolytic enzymes in biological regulation. Proc. Natl Acad. Sci. USA 73:3825-32
2. Polgar L. 1989. General aspects of proteases. In Mechanisms of Protease Action, ed. L Polar, pp. 43-76. Boca Ratan, FL: CRC Press
3. Gross P, Babyak MA, Tolker E, Kaschak M. 1964. Enzymatically produced pulmonary emphysema: a preliminary report. J. Occup. Med. 6:481
4. Chapman HA, Stone OL, Vavrin Z. 1984. Degradation of fibrin and elastin by human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. J. Clin. Invest. 73:806-15
5. Chapman HA Jr, Stahl M, Fair DS, Allen CL. 1988. Regulation of the procoagulant activity within the alveolar compartment of normal human lung. Am. Rev. Resp. Dis. 37:1417-25
6. Nadel JA. 1991. Neutral endopeptidase modulates neurogenic inflammation. Eur. Resp. J. 4:745-54
7. Polgar L, ed. 1989. Metalloproteases. In Mechanisms of Protease Action, pp. 208-210. Boca Ratan, FL: CRC Press
8. Menard R, Storer A. 1992. Oxyanion hole interactions in serine and cysteine proteases. Hoppe-Seyler's Z. Biol. Chem. 373:393-400
9. Matthews BW, Sigler PB, Henderson R, Blow DM. 1967. Three-dimensional structure of tosyl-α-chymotrypsin. Nature 214:652-56
10. Varughese KL, Ahmed FR, Careys PR, Hasnain S, Huber CP, Storer AC. 1989. Crystal structure of papain-E-64 complex. Biochemistry 28:1330-32
11. Mason RW, Wilcox D. 1993. Chemistry of lysosomal cysteine proteases. Adv. Cell Mol. Biol. Membr. 1:81-116
12. Berti PJ, Storer AC. 1995. Alignment/phylogeny of the papain superfamily of cysteine proteases. J. Mol Biol. 246:273-83
13. Thornberry N, Bull HG, Calaycay JR, Chapman KT, Howard AD, et al. 1992. A novel heterodimeric cysteine protease is required for inteleukin-1 beta processing in monocytes. Nature 356:768-74
14. Henkart PA. 1996. ICE family proteases: mediators of all apoptotic cell death? Immunity 4:194-201
15. Saido TC, Sorimachi H, Suzuki K. 1994. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 8:814-22
16. Croall DE, DeMartino GN. 1991. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev. 71:813-47
17. Du X, Saido TC, Tsubuki S, Indig FE, Wiklliams MJ, Ginsberg MH. 1995. Calpain cleavage of the cytoplasmic domain of the integrin beta 3 subunit. J. Biol. Chem. 270:26146-51
18. Sorimachi H, Saido TC, Suzuki K. 1994. New era of calpain research. Discovery of tissue-specific calpains. FEBS Lett. 343:1-5
19. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, et al. 1995. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81:27-40
20. Sebti SM, Mignano JE, Jani JP, Srimatkandada S, Lazo JS. 1989. Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family. Biochemistry 28: 6544-48
21. Sebti SM, DeLeon JC, Lazo JS. 1987. Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase. Biochemistry 26: 4213-19
22. Lazo JS, Boland CJ, Schwartz PE. 1982. Bleomycin hydrolase activity and cytotoxicity in human tumors. Cancer Res. 42:4026-31
23. Joshua-Tor L, Xu HE, Johnston SA, Rees DC. 1995. Crystal structure of a conserved protease that binds DNA: the bleomycin hydrolase, Gal6. Science 269:945-50
24. Musil D, Zucic D, Turk D, Engh RA, Mayr L, et al. 1991. The refined 2.15 AA X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 10:2321-30
25. Kirschke H, Weideranders B, Bromme D, Rinne A. 1989. Cathepsin from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem. J. 264:467-73
26. Fuchs R, Gassen HG. 1989. Nucleotide sequence of human preprocathepsin H, a lysosomal cysteine proteinase. Nucleic Acids Res. 17:9471
27. Joseph LJ, Chang LC, Stemenkovich D, Sukhatme VP. 1988. Complete nucleotide and deduced amino acid sequence of human and murine preprocathepsin L. J. Clin. Invest. 81:1621-29
28. Chan SJ, Segundo BS, McCormick MB, Steiner DF. 1986. Nucleotide and predicted amino acid sequence of cloned human and mouse preprocathepsin B cDNAs. Proc. Natl. Acad. Sci. USA 83:7721-28
29. Fong D, Calhoun DH, Hsieh W-T, Lee B, Wells RD. 1986. Isolation of a cDNA clone for the human lysosomal proteinase cathepsin B. Proc. Natl. Acad. Sci. USA 83:2909-13
30. Barrett AJ, Kirschke H. 1981. Cathepsins B, H, and L. Meth. Enzymol. 80:535-61
31. Shaw E, Dean RT. 1980. The inhibition of macrophage protein turnover by a selective inhibitor of thiol proteases. Biochem. J. 186:385-90
32. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA. 1992. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J. Biol. Chem. 267:7258-62
33. Shi GP, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ. 1995. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC-2. FEBS Lett. 357:129-34
34. Wiederanders B, Bromme D, Kirschke H, Kalkkiner N, Rinne A, et al. 1991. Primary structure of bovine cathepsin S. Comparison to cathepsins L, H, and B. FEBS Lett. 286:189-92
35. Petanceska S, Devi L. 1992. Sequence analysis, tissue distribution, and expression of rat cathepsin S. J. Biol. Chem. 267:26038-43
36. Velasco G, Ferrando AA, Puente XS, Sanchez LM, Lopez-otin C. 1994. Human cathepsin O. Molecular cloning from a breast carcinoma, production of the active enzyme in Escherichia coli, and expression analysis in human tissues. J. Biol. Chem. 269:27136-42
37. McGuire MJ, Lipsky PE, Thiele DL. 1992. Purification and characterization of dipeptidyl peptidase I from human spleen. Arch. Biochem. Biophys. 295:280-88
38. Dikov MM, Springman EB, Yeola S, Serafin WE. 1994. Processing of procarboxypeptidase A and other zymogens in murine mast cells. J. Biol. Chem. 269:25897-904
39. Vernet T, Berti PJ, de Montigny C, Musil R, Tessier DC, et al. 1995. Processing of the papain precursor. The ionization state of a conserved amino acid motif within the pro region participates in the regulation of the intramolecular processing. J. Biol. Chem. 270:10838-46
40. Fox T, de Miguel E, Mort JS, Storer AC. 1992. Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry 31:12571-76
41. Tao K, Stearns NA, Dong J, Wu QL, Sahagian GG. 1994. The pro region of cathepsin L is required for proper folding, stability, and ER exit. Arch. Biochem. Biophys. 311:19-27
42. Baudys M, Meloun T, Gan-Erdene T, Fusek M, Mares M, et al. 1991. S-S bridges of cathepsin B and H from bovine spleen: a basis for cathepsin B model building and possible functional implications for discrimination between exo- and endopeptidase activities among cathepsins B, H and L. Biomed. Biochim. Acta 50:569-77
43. Vernet T, Tessier DC, Chatellier J, Plouffe C, Lee TS, et al. 1995. Structural and functional roles of asparagine 175 in the cysteine protease papain. J. Biol. Chem. 270:16645-52
44. Pisoni RL, Acker TL, Lisowski KM, Lemons RM, Theone JG. 1990. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis. J. Cell Biol. 110: 327-35
45. Reddy VY, Zhang Q-Y, Weiss SJ. 1995. Pericellular mobilization of the tissue-destructive cysteine proteases, cathepsins B, L, and S, by human macrophages. Proc. Natl. Acad. Sci. USA 92:3849-53
46. Baron R, Neff L, Louvard D, Courtoy PJ. 1985. Cell mediated extracellular acidification and bone resorption: evidence to a low pH in resorbing lacunae and localization of a 100 kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 101:2210-28
47. Baron R. 1989. Molecular mechanisms of bone resorption by the osteoclast. Anat. Rec. 224:2317-429
48. Dalaisse JM, Eeckhout Y, Vaes G. 1980. Inhibition of bone resorption in culture by inhibitors of thiol proteinases. Biochem. J. 192:365-68
49. Barrett AJ. 1987. The cystatins: a new class of peptidase inhibitors. Trends Biochem. Sci. 12:193-96
50. 2 subsite of cathepsin B. Biochemistry 33:4384-92
51. Penacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, et al. 1996. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271:1731-34
52. Ray CA, Black RA, Kronheim SR, Green-street TA, Sleath PR, et al. 1992. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 69:597-604
53. Suminami Y, Kishi F, Sekiguchi K, Kato H. 1991. Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem. Biophys. Res. Commun. 181:51-58
54. Takeda A, Yamamoto T, Nakamura Y, Takahashi T, Hibino T. 1995. Squamous cell carcinoma antigen is a potent inhibitor of cysteine proteinase cathepsin L. FEBS Lett. 359:78-80
55. Schneider SS, Schick C, Fish KE, Miller E, Pena JG, et al. 1995. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc. Natl. Acad. Sci. USA 92:3147-51
56. Chapman HA, Munger JS, Shi GP. 1994. Role of thiol proteases in tissue injury. Am. J. Resp. Crit. Care Med. 150:S155-59
57. Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, et al. 1994. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 269:1106-9
58. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, et al. 1995. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. 206:89-96
59. Bromme D, Okamoto K, Wang BB, Biroc S. 1996. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. J. Biol. Chem. 271:2126-32
60. Saneshige S, Mano H, Tezuka K, Kakudo S, Mori Y, et al. 1995. Retinoic acid directly stimulates osteoclastic bone resorption and gene expression of cathepsin K/OC-2. Biochem. J. 309:721-24
61. Mason RW, Johnson D, Barret AJ, Chapman HA Jr. 1986. Elastolytic activity of human cathepsin L. Biochem. J. 122:925-27
62. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. 1991. Human 92 kDA and 72 kDA Type IV collagenases are elastases. J. Biol. Chem. 266:7870-75
63. Murphy G, Cockett ML, Ward RV, Docherty AJP. 1991. Matrix metalloproteinase degradation of elastin, type IV collagen, and proteoglycan. Biochem. J. 277:277-79
64. Baugh RJ, Travis J. 1976. Human leukocyte granule elastase: rapid isolation and characterization. Biochemistry 15:836-41
65. Kao RC, Wehmer NG, Skubitz KM, Gray BH, Hoidal JR. 1988. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produced emphysema in hamsters. J. Clin. Invest. 82:1963-73
66. Xin XQ, Gunesekera B, Mason RW. 1992. The specificity and elastinolytic activities of bovine cathepsins S and H. Arch. Biochem. Biophys. 299:334-39
67. Chapman HA, Stone OL. 1984. Comparison of live human neutrophil and alveolar macrophage elastolytic activity in vitro: relative resistance of macrophage elastolytic activity to serum and alveolar protease inhibitors. J. Clin. Invest. 74:1693-700
68. Gelb B, Shi GP, Chapman HA, Desnick RJ. 1996. Pycnodysostosis is caused by a deficiency of cathepsin K. Science. 273:1236-38
69. Edelson JG, Obad S, Geiger R, On A, Artul HJ. 1992. Pycnodysostosis. Orthopedic aspects with a description of 14 new cases. Clin. Orth. 280:263-76
70. Aronson DC, Heymans HS, Bijlmer RP. 1984. Cor pulmonale and acute liver necrosis, due to upper airway obstruction as part of pycnodysostosis. Eur. J. Pediatr. 141:251-53
71. Gelb BD, Edelson JG, Desnick RJ. 1995. Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping. Nat. Genet. 10:235-37
72. Polymeropoulos MH, Ortiz De Luna RI, Ide SE, Torres R, et al. 1995. The gene for pycnodysostosis maps to human chromosome 1cen-q21. Nat. Genet. 10:238-39
73. Fukuda Y, Kawamoto M, Yamamoto A, Ishizaki M, Basset F, Masugi Y. 1990. Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum. Pathol. 21:1252-61
74. Janoff A. 1985. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am. Rev. Resp. Dis. 132:417-33
75. Tetley TD. 1993. New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease. Thorax 48:560-65
76. Snider GL. 1992. Emphysema: the first two centuries - and beyond. A historical overview, with suggestions for future research: Part 2. Am. Rev. Resp. Dis. 146:1615-22
77. Ogushi F, Hubbard RC, Vogelmeier C, Fells GA, Crystal RG. 1991. Risk factors for emphysema. Cigarette smoking is associated with a reduction in the association rate constant of lung alpha-1-antitrypsin for neutrophil elastase. J. Clin. Invest. 87:1060-65
78. Belaaouaj A, Shapiro SD. 1996. Identification of differentially expressed genes in lungs of mice following exposure to cigarette smoke. Resp. Crit. Care Med. 153:A30 (Abstr.)
79. Silverman P, Chapman H, Drazen J, O'Donnell W, Reilly J, et al. 1996. Early-onset chronic obstructive pulmonary disease (COPD): preliminary evidence for genetic factors other than PI type. Resp. Crit. Care Med. 153:A48 (Abstr.)
80. Shi GP, Webb AC, Foster KE, Knoll JHM, Lemere CA, et al. 1994. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J. Biol. Chem. 269:11530-36
81. Morton PA, Zacheis ML, Giacoletto KS, Manning JA, Schwartz BD. 1995. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J. Immunol. 154:137-50
82. Roche PA, Marks MS, Cresswell P. 1991. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354:392-394
83. Lamb C, Cresswell P. 1992. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. J. Immunol. 148:3478-82
84. Guagliardi LE, Koppelman B, Blum JS, Marks MS, Cresswell P, Brodsky FM. 1990. Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment. Nature 343:133-39
85. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ. 1991. Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 349:669-75
86. Amigorena S, Drake JR, Webster P, Mellman I. 1994. Transient accumulation of new class IIMHC molecules in a novel endocytic compartment in B lymphocytes. Nature 349:113-20
87. Tulp A, Verwoerd D, Dobberstein B, Ploegh HL, Peters J. 1994. Isolation and characterization of the intracellular MHC class II compartment. Nature 349:120-26
88. West MA, Lucocq JM, Watts C. 1994. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 369:147-51
89. Bijlmakers M-JE, Benaroch P, Ploegh HL. 1994. Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J. Exp. Med. 180:623-29
90. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622-27
91. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. 1992. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474-76
92. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, et al. 1992. Predominant naturally processed peptides bound to HLA-DRI are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764-68
93. Ghosh P, Amaya M, Merlins E, Wiley DC. 1995. The structure of an intermediate in class II maturation: CLIP bound to HLA-DR3. Nature 378:457-62
94. Denzin LK, Cresswell P. 1995. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers. Cell 82:155-65
95. Sherman MA, Weber DA, Jenson PE. 1995. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3:197-205
96. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, et al. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:802-6
97. Cresswell P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259-93
98. Roche PA, Cresswell P. 1990. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345:615-18
99. Roche PA, Cresswell P. 1991. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc. Natl. Acad. Sci. USA 88:3150-54
100. Blum JS, Cresswell P. 1988. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc. Natl. Acad. Sci. USA 85:3975-79
101. Nguyen QV, Knapp W, Humphreys RE. 1988. Inhibition by leupeptin and antipain of the intracellular proteolysis of Ii. Hum. Immunol. 24:153-63
102. Nguyen QV, Humphreys RE. 1989. Time course of intracellular associations, processing, and cleavages of Ii forms and class II major histocompatibility complex molecules. J. Biol. Chem. 264:1631-37
103. Humbert M, Bertolino P, Forquet F, Rabourdine-Comb C, Gerlier D, et al. 1993. Major histocompatibility complex class II-restricted presentation of secreted and endoplasmic reticulum resident antigens requires the invariant chains and is sensitive to lysosomotropic agents. Eur. J. Immunol. 23:3167-72
104. Benaroch P, Mamadi Y, Raposo G, Ito K, Miwa K, et al. 1995. How MHC class II molecules reach the endocytic pathway. EMBO J. 14:37-49
105. Neefjes JJ, Ploegh HL. 1992 Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistant αβ heterodimers in endosomes. EMBO J. 11:411-16
106. Demotz S, Danieli C, Wallny H-J, Majdic O. 1994. Inhibition of peptide binding to DR molecules by a leupeptin-induced invariant chain fragment. Mol. Immunol. 31:885-93
107. Buus S, Werdelin O. 1986. A group-specific inhibitor of lysosomal cysteine proteinases selectively inhibits both proteolytic degradation and presentation of the antigen dinitrophenyl-poly-L-lysine by guinea pig accessory cells to T cells. J. Immunol. 136:452-58
108. Diment S. 1990. Different roles for thiol and aspartyl proteases in antigen presentation of ovalbumin. J. Immunol. 145:417-22
109. Riese RJ, Wolf PR, Bromme D, Natkin LR, Villadangos JA, et al. 1996. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4:357-65
110. Palmer JT, Rasnick D, Klaus JL, Bromme D. 1995. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38:3193-96
111. Lanzavecchia A. 1990. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu. Rev. Immunol. 8:773-93
112. Qiu Y, Xu X, Wandinger-Ness A, Dalke DP, Pierce SK. 1994. Separation of subcellular compartments containing functional forms of MHC class II. J. Cell Biol. 119:531-42
113. Barnes KA, Mitchell RN. 1995. Detection of functional class II-associated antigen: role of a low density endosomal compartment in antigen processing. J. Exp. Med. 181:1715-27
114. Vidard L, Rock KL, Benacerraf B. 1991. The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors. J. Immunol. 147:1786-91
115. Demotz S, Matricardi PM, Irle C, Panina P, Lanzavecchia A, Corradin G. 1989. Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways. J. Immunol. 143:3881-86
116. Rodriguez GM, Diment S. 1992. Role of cathepsin D in antigen presentation of ovalbumin. J. Immunol. 149:2884-98
117. van Noort JM, Boon J, van der Drift ACM, Wagenaar JPA, Boots AMH, Boog CJP. 1991. Antigen processing by endosomal proteases determines which sites of sperm-whale myoglobin are eventually recognized by T cells. Eur J. Immunol. 21:1989-96
118. Bennett K, Levine T, Ellis JS, Peanasky RJ, Samloff IM, et al. 1992. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur. J. Immunol. 22:1519-24
119. Heft PG, Heining S, Nelson DJ, Sedgwick JD. 1994. Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of conducting airways. J. Immunol. 153:256-61
120. Holt PG. 1993. Regulation of antigen-presenting cell function(s) in lung and airway tissues. Eur. Res. J. 6:120-29